DCC
DCC (Netrin receptor DCC) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Hepatocellular carcinoma and 3 more.
Overview
Receptor for netrin required for axon guidance. Mediates axon attraction of neuronal growth cones in the developing nervous system upon ligand binding. Its association with UNC5 proteins may trigger signalling for axon repulsion.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.59 (direct and indirect evidence; datatypes literature 0.87, animal model 0.70, genetic association 0.62, somatic mutation 0.63). IntOGen calls it a driver in 5 cohorts (2 activating, 3 loss-of-function), covering Colorectal Adenocarcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, Prostate Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · DCC (Netrin receptor DCC) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Hepatocellular carcinoma and 3 more.
- 1 · What it is
DCC (Netrin receptor DCC) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Hepatocellular carcinoma and 3 more.
- 2 · What goes wrong in cancer
Receptor for netrin required for axon guidance. Mediates axon attraction of neuronal growth cones in the developing nervous system upon ligand binding.
- 3 · How drugs use it
No product in this corpus aims at DCC yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:2701 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P43146 (protein name, function text, keywords and locations (REST API)); CIViC gene DCC (1 evidence items, 0 assertions, 1 variants; diseases: Colorectal Cancer (GraphQL API, CC0)); Open Targets ENSG00000187323 (association with cancer (MONDO_0004992) 0.59; per-cancer scores at or above 0.5: colorectal cancer 0.51 (GraphQL API, CC0)); IntOGen DCC (driver in 5 cohorts (Act 2, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Receptor for netrin required for axon guidance. Mediates axon attraction of neuronal growth cones in the developing nervous system upon ligand binding. Its association with UNC5 proteins may trigger signalling for axon repulsion. It also acts as a dependence receptor required for apoptosis induction when not associated with netrin ligand. Implicated as a tumour suppressor gene. Location: Membrane (UniProt). Locus 18q21.2 (HGNC).
- Colorectal cancer: Open Targets association 0.51 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)
- Prostate cancer: IntOGen driver in 1 cohort (PRAD)
- Oesophageal and junctional adenocarcinoma: IntOGen driver in 1 cohort (ESCA)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"DCC" OR ABSTRACT:"DCC" OR TITLE:"DCC netrin 1 receptor" OR ABSTRACT:"DCC netrin 1 receptor" OR TITLE:"Netrin receptor DCC" OR ABSTRACT:"Netrin receptor DCC" OR TITLE:"IGDCC1" OR ABSTRACT:"IGDCC1" OR TITLE:"NTN1R1" OR ABSTRACT:"NTN1R1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DCC, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetSMAD4
Shares Colorectal cancer (KEGG map), Oesophageal cancer, CIViC, IntOGen.
- TargetCDX2
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, CIViC, IntOGen.
- TargetNBEA
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Hepatocellular carcinoma, IntOGen.
- TargetAPC
Shares Colorectal cancer (KEGG map), Oesophageal cancer, Hepatocellular carcinoma, CIViC.
- TargetCDH11
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Hepatocellular carcinoma, IntOGen.
- TargetHLA-B
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, CIViC, IntOGen.
- TargetNCOA2
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Prostate cancer.
- TargetEPHA3
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Prostate cancer.